Mirbeg-S 25 Tablet ER is a sustained-release oral formulation of a fixed-dose combination of mirabegron (25mg) and solifenacin (5mg) indicated for the treatment of overactive bladder (OAB) symptoms, including urgency, frequency, and incontinence. This once-daily tablet is designed to provide prolonged release of the active ingredients, allowing for a consistent therapeutic effect throughout the day. Mirabegron, a beta-3 adrenergic receptor agonist, works by increasing the bladder's capacity and improving bladder muscle function, while solifenacin, a muscarinic receptor antagonist, reduces the frequency and urgency of bladder contractions. The combination of these mechanisms of action provides a comprehensive approach to managing OAB symptoms, including those associated with urgency incontinence. The tablet is suitable for patients who have not responded adequately to other OAB treatments or who are experiencing intolerable side effects. As with any medication, patients should consult their healthcare provider for guidance on the proper use and potential interactions of Mirbeg-S 25 Tablet ER.